Lipocine licenses TLANDO franchise to Verity Pharma for $11M upfront, up to $259M milestones plus royalties

Lipocine Inc.

Exclusive US/Canada rights to TLANDO and TLANDO XR; Lipocine receives $11M license fee ($2.5M paid, $5M due Feb 1, 2024).
Eligible for up to $259M in development and sales milestones plus tiered royalties of 12–18% on US/Canada net sales.
Commercialization transitions to Verity Pharma effective Feb 1, 2024; Verity handles all regulatory and marketing obligations.
Lipocine retains all rights outside US/Canada and all non-TRT indications globally.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lipocine Inc. entered into License Agreement with Gordon Silver Limited and Verity Pharmaceuticals, Inc. valued at $11 million license fee (effective 2024-01-12).

Action: entry
Agreement: license
Counterparty: Gordon Silver Limited and Verity Pharmaceuticals, Inc.
Value: $11 million license fee
Effective: 2024-01-12

Exact text from the filing

On January 12, 2024, Lipocine Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Gordon Silver Limited (“GSL”) and Verity Pharmaceuticals, Inc. (“Verity Pharma”)

View on SEC.gov

306 material agreements filed in the last 30 days. Browse all material agreements →

Lipocine Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-002831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.